Skip to content
Screener

EPS (Basic) at other companies

Amgen logo
AmgenAMGN
$4.40+65.4%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$0.73-15.9%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$1.69-109%
PVL
Palvella TherapeuticsPVLA
-$1.20-62.2%
Regenxbio logo
RegenxbioRGNX
$0.43+131%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0.14-88.7%

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.55B+81.7%
Enterprise value$2.5B+90.9%
P/S35.9×-4,565×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed November 12, 2024.

Filed
Nov 12, 2024
Fiscal quarter
Q3 FY2024
Calendar quarter
Q3 2024
Accession
0001590750-24-000023
Line itemThree Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023
Interest and other expense(1,004)(600)(2,188)(931)
Other income, net6,7913,56421,33912,098
Net loss$(76,689)$(47,660)$(190,224)$(170,874)
Net loss per share, basic and diluted$(1.15)$(1.09)$(2.98)$(3.97)
Weighted-average shares used to compute basic and diluted net loss per share66,420,06343,654,57763,800,79843,057,658
Comprehensive loss:
Net loss$(76,689)$(47,660)$(190,224)$(170,874)
Other comprehensive gain:

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Viridian Therapeutics, Inc.'s EPS (basic)?
Viridian Therapeutics, Inc. (VRDN) reported EPS (basic) of -$1.15 in Q3 2024.
How has Viridian Therapeutics, Inc.'s EPS (basic) changed year-over-year?
Viridian Therapeutics, Inc.'s EPS (basic) decreased by 5.5% year-over-year, from -$1.09 to -$1.15.
What is the long-term trend for Viridian Therapeutics, Inc.'s EPS (basic)?
Over 2 years (2021 to 2023), Viridian Therapeutics, Inc.'s EPS (basic) has grown at a -13.4% compound annual growth rate (CAGR), from -$7.08 to -$5.31.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Viridian Therapeutics, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude